The development of targeted therapeutics for lung cancer greatly benefits from abnormal tyrosine phosphorylation catalyzed by RPTKs, such as the Epidermal Growth Factor Receptor (EGFR). The gene discussed is EGFR; the disease is lung carcinoma.